

Trust Headquarters Russell's Hall Hospital Dudley West Midlands DY1 2HQ

Ref: FOI-062023-000124

Date: 7/7/23

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000, please see response below:-

A. In the 4 months, Mar23-Jun23, the following number of patients were treated with the listed dru			
Treatment	Number of Patients		
Erenumab (Aimovig) - any disease	0		
Eptinezumab (Vyepti) - any disease	0		
Fremanezumab (Ajovy) - any disease	22		
Galcanezumab (Emgality) - any disease	0		
Rimegepant (Vydura) - any disease	0		
Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY	55		

B. In the 4 months, Mar23-Jun23, the following number of patients were treated with the listed drugs for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:

Drugs	Chronic Migraine (15+ headache days per month)	Episodic Migraine (4- 15 headache days per month)
Erenumab	0	0
Eptinezumab	0	0
Fremanezumab	0	22
Galcanezumab	0	0
Rimegepant	0	0
Botulinum Toxin	51	4

FOI/REF FOI-

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager Trust Headquarters Russell's Hall Hospital Dudley West Midlands DY1 2HQ Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF Tel: 0303 123 1113 www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team The Dudley Group NHS Foundation Trust